Status:
UNKNOWN
EC50 of Dexmedetomidine in Deep Brain Stimulation Implantation of Patients With Parkinson's Disease
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
PD - Parkinson's Disease
Eligibility:
All Genders
50-80 years
Phase:
PHASE4
Brief Summary
Dexmedetomidine (DEX) sedation is widely used in deep brain stimulation implantation (DBSI) of patients With Parkinson's disease. However, intraoperative application of DEX may affect the discharge ac...
Detailed Description
Deep brain stimulation (DBS) is an effective treatment to improve the motor symptoms of Parkinson's disease (PD). Subthalamic nucleus (STN) is one of the most commonly used targets in the treatment of...
Eligibility Criteria
Inclusion
- 50-80 years old, ASA grade II-III;
- Bilateral STN-DBS of patients with Parkinson's disease;
- Signed informed consent.
Exclusion
- Obstructive sleep apnea;
- BMI \> 30kg/m2;
- Estimated difficult airway;
- Severe preoperative anxiety;
- Serious dysfunction of important organs such as heart, liver and kidney;
- previous allergy to dexmedetomidine;
- Pregnant or lactating women.
Key Trial Info
Start Date :
May 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05376761
Start Date
May 31 2022
End Date
December 31 2023
Last Update
June 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan hospital
Beijing, Beijing Municipality, China